ABSTRACT – Background: Surgical strategy to increase the number of liver transplants in the pediatric population is the ex-situ liver transection (reduction or split). However, it is associated with complications such as hemorrhage and leaks. The human fibrinogen and thrombin sponge is useful for improving hemostasis in liver surgery. Aim: Compare pediatric liver transplants with ex-situ liver transection (reduction or split) with or without the human fibrinogen and thrombin sponge. Methods: Was performed a prospective analysis of 21 patients submitted to liver transplantation with ex-situ liver transection with the application of the human fibrinogen and thrombin sponge in the wound area (group A) and retrospective analysis of 59 patients without the sponge (group B). Results: The characteristics of recipients and donors were similar. There were fewer reoperations due to bleeding in the wound area in group A (14.2%) compared to group B (41.7%, p=0.029). There was no difference in relation to the biliary leak (group A: 17.6%, group B: 5.1%, p=0.14). Conclusion: There was a lower number of reoperations due to bleeding of the wound area of the hepatic graft when the human fibrinogen and thrombin sponge were used.

INTRODUCTION

Pediatric liver transplantation needs to deal with the difficulty of finding small deceased donors in whom the hepatic graft fits the size of the recipient and organ shortage is a problem described by liver transplant teams, making the mortality in the awaiting list a reality.

As alternatives to small recipient cases - in an attempt to increase the supply of liver grafts - techniques were developed, such as liver transplantation with ex-situ liver transection of the graft from the deceased donor. When talking about liver transplantation with ex-situ liver transection, these are two possible procedures: hepatic reduction or split.

Hepatic reduction, described by Bismuth et al. in 1984, in which, from a cadaveric donor the hepatic graft fits the size of the recipient and organ shortage is a problem described by liver transplant teams, making the mortality in the awaiting list a reality.

As alternatives to small recipient cases - in an attempt to increase the supply of liver grafts - techniques were developed, such as liver transplantation with ex-situ liver transection of the graft from the deceased donor. When talking about liver transplantation with ex-situ liver transection, these are two possible procedures: hepatic reduction or split. However, it is associated with complications such as hemorrhage and leaks. The human fibrinogen and thrombin sponge is useful for improving hemostasis in liver surgery.

Aim: Compare pediatric liver transplants with ex-situ liver transection (reduction or split) with or without the human fibrinogen and thrombin sponge. Methods: Was performed a prospective analysis of 21 patients submitted to liver transplantation with ex-situ liver transection with the application of the human fibrinogen and thrombin sponge in the wound area (group A) and retrospective analysis of 59 patients without the sponge (group B). Results: The characteristics of recipients and donors were similar. There were fewer reoperations due to bleeding in the wound area in group A (14.2%) compared to group B (41.7%, p=0.029). There was no difference in relation to the biliary leak (group A: 17.6%, group B: 5.1%, p=0.14). Conclusion: There was a lower number of reoperations due to bleeding of the wound area of the hepatic graft when the human fibrinogen and thrombin sponge were used.

ABCD Arq Bras Cir Dig 2016;29(4):236-239
Currently, the ex-situ liver transection technique achieves good results in the literature, with survival rates similar to the results of transplants with whole grafts, but its use is not free of complications such as increased bleeding of the wound area of the graft, with greater use of blood products and biliary leak.

The human fibrinogen and thrombin sponge (Tachosil®) is a material to aid in surgical hemostasis, consisting of a matrix of collagen associated with a layer of plasma components such as coagulation factors, fibrinogen and fibrin. Its use in liver surgery was described in studies, showing that after hepatectomy its use obtained fast and effective hemostasis in the wound area when compared to other methods. New articles describe the use of sponge in the field of liver transplantation with good results in relation to hemostasis and biliary leak.

The objective of this study was to compare pediatric liver transplantation with the ex-situ liver transection with or without the use of the human fibrinogen and thrombin sponge.

METHODS

The project was approved by the Research Ethics Committee of the Federal University of São Paulo/Hospital São Paulo, with number 38311/2012.

A prospective study of pediatric patients submitted to liver transplantation with the ex-situ liver transection technique and with the use of the human fibrinogen and thrombin sponge was carried out at Hospital São Paulo, Escola Paulista de Medicina - UNIFESP, São Paulo, SP, Brazil, from January 2012 to May 2016. The control group was formed by a historical cohort, with prospective data collection, starting in January 2004, of all patients submitted to liver transplantation with ex-situ liver transection technique without the use of the human fibrinogen and thrombin sponge in this same service.

The study included 80 patients and divided into two groups: the first, classified as group A, was composed of 21 patients submitted to the transplantation with the use of the human fibrinogen and thrombin sponge; and in the control group (group B) were included 59 patients submitted to the transplantation without the use of fibrinogen sponge and human thrombin.

Inclusion criteria were children of up to 18 years of age, of both genders, submitted to liver transplantation with ex-situ liver transection technique independent of indications of liver transplantation. Patients older than 18 years and cases in which the parents or guardians refused to sign the free and informed consent form were excluded.

Potential donors were selected for hepatic transplantation with the ex-situ liver transection technique when, if possible, they fit within the criteria of this institution: under 50 years of age, hemodynamic stability, less than four days in the intensive care, ALAT (U/l) and ASAT (U/l) levels less than twice normal, GGT below 50 IU/l, sodium levels below 160 mmol/l and less than 30% fat infiltration in the macroscopic analysis. Due to the severity of the recipients and the urgency of a liver graft for transplantation, not all donors met these criteria.

Aiming for the most appropriate matching between donor and recipient, the size, weight and BMI data of both were taken into account in the decision to perform the liver transection. The logistics between liver graft extraction, liver transection (reduction or split) on an auxiliary table, and graft implantation were designed to achieve maximum cold ischemia time of 12 h.

After liver graft revascularization, primary hemostasis and raffia of the bile ducts of the wound area were performed. According to the manufacturer’s instructions, the previously moistened sponge and was applied the yellow side, on which the active principles of the product were found, to the wound surface of the liver graft. Sponge compression was carried out with the aid of a wet compress for about 2 min in order to obtain a correct sponge fixation and local hemostasis.

When necessary, because of the extent of the wound area being larger than the surface of the sponge, more than one was used and the application process was repeated (Figure 2).

RESULTS

The two groups were similar in terms of demographic characteristics, including age, gender, diagnosis of liver disease, weight, height, blood typing and MELD range.

In relation to the donors, except for the level of bilirubin (mg/dl), which was higher in group A (0.71±0.55) than in group B (0.47±0.37), but both above the normality, there was no difference in the other characteristics and both group were similar to age (years), gender, body mass index (BMI), use of inhaled drugs, alcohol consumption (mg/dl), creatinine (mg/dl), urea (mg/dl), ALAT (U/l), ASAT (U/l), bilirubin (mg/dl), alkaline

Past data from transplants with whole grafts were used as a basis for comparison. The analyzed data are represented in mean, median, standard deviation and percentage. Student’s t-test, chi-square, Fisher exact, Mann-Whitney and Kaplan Meier survival curve were applied when indicated. The statistical analysis program SPSS version 2.0 was used, with p <0.05 being considered significant.
phosphatase (U/l) and GGT (U/l).

Group A consisted of 18 (85.7%) patients submitted to the split technique and three (14.3%) to the reduction technique; in group B, 36 (61%) patients were submitted to the split technique and 23 (39%) to the reduction technique (p = 0.056).

The parameters analyzed in the surgical procedure (Table 1) showed that both groups received red blood cell transfusion, and the median use of blood products (ml/kg) was 35.1 in group A and 36.5 in group B, without statistically significant difference (p = 0.83).

### TABLE 1 - Liver transplantation data

|                      | Group A (n = 21) | Group B (n = 59) | p     |
|----------------------|-----------------|-----------------|-------|
| Use of red blood cells |                 |                 |       |
| With sponge           | 100 %           | 100 %           | 1     |
| Without sponge        |                 |                 |       |
| Hemoderivative (ml/kg)| 35.1            | 36.5            | 0.83  |
| Reoperation due to bleeding of the wound area | 14.2% | 41.7% | 0.029 |
| Collections           | 14.28%          | 9.75%           | 0.68  |
| Bile leak of the wound area | 5.88% | 5.12% | 0.87  |

When the reoperations by bleeding of the wound area were analyzed, there was a lower frequency in group A (14.2%) than in B (41.7%), with a statistically significant difference (p = 0.029).

Regarding the biliary leak and collection of the wound area, as well as the type of treatment indicated for the collection, such as reoperation, puncture and drainage of the collections, there was no statistical difference when comparing the two groups.

Regarding the early survival in 30 days, comparing the two groups, group A presented survival of 80.9% in 30 days and the B 87.7%, with no statistically significant difference (p = 0.328). Early 30-day survival of liver grafts was also similar, comparing the two groups (group A: 76.1% and group B: 78.4%, p = 0.668).

### DISCUSSION

The two groups studied did not present statistical differences regarding the demographic characteristics of the donors and recipients, forming two groups similar and comparable for possible outcomes. The techniques of ex-situ liver transection were similar in reduction and split.

An alternative to the ex-situ split technique would be the use of split in-situ, in which the liver graft is divided with the donor still the heart beating. This technique has already been described in the literature[14,15,18,21,25,36], and it is known that there is an increase of about 2 h during the harvesting operation when employed[10,22], in addition to the need for adequate equipment to perform this procedure in the hospital where the capture is performed.

These conditions are difficult to find in Brazil due to their extension and non-standardization of health services, so this technique has been little used in the country. The Pittsburgh transplant group published a comparison between in-situ and ex-situ split techniques in 2000, showing no difference in patient survival and hepatic graft survival[21].

Hemotransfusion frequency was observed in 100% of patients in both groups during liver transplantation, red blood cell transfusion volume was statistically similar, and the median use of blood products (ml/kg) was 35.1 in group A and 36.5 in group B, with no statistically significant difference (p = 0.83).

In a study published in 2010, Toti et al. compared the use of human fibrinogen and thrombin sponge with fibrin glue in the wound area of patients submitted to liver transplantation with the ex-situ split technique. The authors described no difference in the need for the use of blood transfusion between the two groups, but did not demonstrate data of transfusion at work and only cited this information during the text[25].

When the reoperations by bleeding of wound area were analyzed we observed that in group A - where the human fibrinogen and thrombin sponge were applied - the reoperation rate was lower (14.2%) than in the group B (41.7%, p = 0.029), demonstrating that this instrument may help in the hemostasis of the wound area of patients submitted to pediatric liver transplantation with the ex-situ liver transection technique (reduction or split).

In the literature, articles involving the use of this sponge for hemostasis of the wound area in hepatectomy and in liver transplants with the ex-situ liver transection technique and/or living donor, corroborate this finding[5,12,14,21,25,28,36].

In 2008 a traditional pediatric transplant group in Belgium published a report of the use of human fibrinogen and thrombin sponge in four children undergoing liver transplantation using the liver transection technique (two received the left segment of alive donor and two a reduced hepatic graft). However, it was a series of cases without a control group and the author’s opinion is that the human fibrinogen and thrombin sponge used on the wound area of the graft leads to a good and effective hemostasis, which occurs by describing the use of only one concentrate of red blood cells per patient during the transplantation, as no patient presented bleeding in the postoperative period[21].

In 2011 Mirza et al. published a prospective and multicenter study analyzing the use of the human fibrinogen and thrombin sponge in a population composed of individuals submitted to liver transplantation with the ex-situ liver transection technique and others to hepatectomy. Sixteen patients were included, 13 of whom underwent liver transplantation. The authors demonstrated good hemostasis of the wound area with the use of the human fibrinogen and thrombin sponge within 3 min in 81% of the patients studied[25]. An interesting point was the way of conducting the study, since the population planned for the analysis was 40 patients. However, during the study, it was interrupted due to the fact that, as the authors wrote, it was evident that the data collected were related to the underlying liver disease or to the surgical procedure, and not to the use of the human fibrinogen and thrombin sponge[25].

In this study, there was no statistically significant difference in the biliary leak rate of the wound area, as well as in the collection area near the wound area between the group that used the sponge (9.88% and 14.28%, respectively), and the group that did not use the sponge (5.12% and 9.75%, respectively, p = 0.87 and p = 0.68, respectively).

Biliary leak in hepatic transplantation is an important cause of morbidity. Literature rates vary from 5-10% of liver transplants with whole liver and are directly related to complications of the hepatic artery[5,16,22,31]. In cases of liver transplantation with the ex-situ liver transection technique (reduction or split), these rates may increase[10] to 18.8%, as described by Diamond et al. in the year 2007[25].

In the literature, the use of human fibrinogen and thrombin sponge and its relation with biliary leak and collection of the wound area is still controversial.

Totti et al., in a retrospective study in 2010 demonstrated a reduction in the biliary leak rate in adult patients submitted to liver transplantation with split and sponge use in the wound area compared to fibrin glue use in the wound area, reducing the rate of leak of 43.75% without the use of the sponge, to 6.25% with its use[16].

On the other hand, Mirza et al. demonstrate a rate of 12.5% of reoperation due to bile leak of the wound area in pediatric patients submitted to liver transplantation even with the use of the human fibrinogen and thrombin sponge in the wound area[25].

It was studied the early survival in 30 days, because after this period the human fibrinogen and thrombin sponge has been absorbed and is no longer present in the patients’ bodies. Both groups presented 30-day mortality and graft loss in 30 days similar, with no statistically significant difference. Patient survival at 30 days in group A was 80.9% and in B,
87.7% (p=0.32). The graft survival in group A was 76.1% and in B, 78.4% (p=0.668). Regarding patient and graft survival in 30-day period, the values are similar to those presented by the other authors in the literature. The one-year survival of pediatric patients undergoing liver transplantation with the ex-situ liver and graft transection technique is described in the literature in about 73% and 63%\(^2\), and may reach 91% and 90% in a highly specialized center. A review article on liver transplantation with the split technique, published in 2003, presented data from authors with rates referring to one-year survival of patients and grafts ranging from 76% to 100% and 66% to 100%\(^2\).

**CONCLUSION**

Comparing pediatric liver transplantation with the ex-situ liver transection technique (reduction or split) with or without the use of the human fibrinogen and thrombin sponge, was observed a smaller number of reoperations due to bleeding of wound area of the liver graft when the human fibrinogen and thrombin sponge were used.

**REFERENCES**

1. Abradelo MRS, Caso O, Álvaro E, Moreno E, and Jiménez C. Split Liver Transplantation: Where? When? How? Transplantation Proceedings, 2012; 44: p. 15-13.
2. Abbas Rana, ZP; Halazun K, Cotton R, Gueitau, J; Courtney CN, O'Mahony CA, John A. Goss, Pediatric Liver Transplant Center Volume and the Likelihood of Transplantation, Pediatrics, 2015, 136(1): p. 99-107.
3. ABTO, Associação Brasileira de Transplante de Órgãos Registro Brasileiro de Transplantes. 2015.
4. Bismuth H, Reduced-sized orthotopic liver graft in hepatic transplantation in children. Surgery Gynecology Obstetrics, 1984. 159: p. 283-90.
5. Briceño JNA, Cirra R, Diaz-Nieto R, Sánchez-Hidalgo JM, Luque A, Rufián S, López-Cillero P. A prospective study of the efficacy of clinical application of a new carrier-bound fibrin sealant after liver resection. Archives of Surgery, 2010. 145 (5): p. 482-488.
6. Broering DC, Shulteam J, Fischer L. Split liver transplantation HPB, 2004. 6(2): p. 76-82.
7. Dalal, AR. Split liver transplantation: What’s unique? World Journal of Gastroenterology, 2015. 5(3): p. 89-94.
8. Diamond IR, Fecteau A, Millis JM, Losanoff JE, Ng V, Anand R, Song. Impact of graft type on outcome in pediatric liver transplantation: a report From Studies of Pediatric Liver Transplantation (SPLIT). Annal of Surgery, 2007. 246: p. 301-10.
9. Dulai DF, Ribeiro Jr MAF. Biliary Complications Following Deceased and Living Donor Liver Transplantation: A Review. Transplantation Proceedings, 2010. 42: p. 517-20.
10. Feifer FR, Fonseca EA, Seda-Neto J, Chachparg P. Biliary complications after pediatric liver transplantation: Risk factors, diagnosis and management. World Journal of Gastroenterology, 2015. 7(18): p. 2162-70.
11. Feria FAL, Di Sandro S, Mangoni I, Poli C, Concone G, Cusumano C, et al. Split-Liver Full-Left Full-Right: Proposal for an Operative Protocol. Transplantation Proceedings, 2014. 46: p. 2279-82.
12. Fischer LSC, Broselich CE, de Hemptinne B, Klempnauer J, Mischinger HJ, Gassel HJ, et al. Hemostatic efficacy of TachoSil in liver resection compared with argon beam coagulator treatment: An open, randomized, prospective, multicenter, parallel-group trial. Surgery, 2011. 149: p. 48-55.
13. Foster RMZ, Trotter JF. Expanding Donor Options: Marginal Living, and Split Donors: Clinics in Liver Disease, 2007. 11: p. 417-29.
14. Frilling A, S.G., Mischinger HJ, de Hemptinne B, Kockjaer M, Klempnauer J, Thörne A, Glooor B, Beckebaum S, Ghaffar MF, Broselich CE., Effectiveness of a new carrier bound fibrin sealant versus argon beamer as haemostatic agent during liver resection a randomised prospective trial. Langenbecks Archives of Surgery, 2005. 390: p. 114-20.
15. Garcia-Valdecasas JC. Split and living donor liver transplantation. Digestive and Liver Disease Supplements, 2009. 3: p. 93-95.
16. Gataca M, Biliary Complications after Orthotopic Liver Transplantation: A Review of Incidence and Risk Factors. Transplantation Proceedings, 2012. 44: p. 1545-49.
17. Gong, XCN. Partial liver transplantation. Frontier in Medicine, 2011. 5(1): p. 1-7.
18. Halac E, Quiroz E, Alvarez F, Espinoza JL, Romero P, Nievas F, et al. Split Liver Transplantation: Report of Right and Left Graft Outcomes From a Multicenter Argentinian Group. Liver Transplantation, 2016. 22(p. 63-70.
19. J-Q Y, Becker T., Cheng H, Hong P, Hong-Wei L, Klempnauer J. Split Liver Transplantation: a reliable approach to expand donor pool. Hepatobilia ry&Pancreatic Diseases International, 2005. 4: p. 339-44.
20. John F, Renz HY, Reichert PR, Hisatak GH, Farmer DG, Emond JC and Busuttil RW, Split-Liver Transplantation: A Review. American Journal of Transplantation 2003. 3: p. 1235-33.
21. Lacanana FBA, Reding R. A new biological mesh for cut surface hemostasis in liver transplantation using technical variants. Pediatric Transplantation, 2008. 12: p. 520-22.
22. Lastovicková J, Peregrin J, Biliary Stenures after Orthotopic Liver Transplantation: Longer-Term Results of Percutaneous Treatment with Patients with Nonfeasible Endoscopic Therapy. Transplantation Proceedings, 2012. 44: p. 1379-84.
23. Lauterio A, Di Sandro S, Concone G, De Carli R, Giacomoni A, De Carlo L. Current status and perspectives in split liver transplantation. World Journal of Gastroenterology, 2015. 21(9): p. 11015-13.
24. Majella MB, Doyle EM, Lin Y, Vachharaanjani N, Shenoy S, Anderson C, et al. Outcomes with Split Liver Transplantation Are Equivalent to Those With Whole Organ Transplantation. Journal of American College of Surgeons, 2008. 207: p. 102-10.
25. Mirza D, Millar AWJ, Sharif K, Villa-Melendez, Rela M, Heanton N. The Use of TachoSil in Children Undergoing Liver Resection With or Without Segmental Liver Transplantation. European Journal of Pediatric Surgery 2011. 21(2): p. 111-15.
26. Osoawa H, S.V.L, Fawcett J, Strong RW and Looi C. Outcomes of split versus reduced-size grafts in pediatric liver transplantation. Journal of Gastroenterology and Hepatology, 2005. 20: p. 1800-50.
27. Pichlmayr RB, Gubernatis G, Haus J, Bunzendahl H. Transplantation of a donor liver to 2 recipients (splitting transplantation)-a method in the further development of segmental liver transplantation. Langenbecks Archives of Surgery, 1988. 373: p. 127-130.
28. Reyes JGD, Mazariegos GV, Casavilla A, Sindhi R, Bueno J, Madariaga J, Fung JH. Split-Liver Transplantation: a comparison of ex vivo and in situ techniques. Journal of Pediatric Surgery, 2000. 35: p. 283-90.
29. Rickelbacher ABS, Lesurtel M, Frilling A, Efficacy of TachoSil a fibrin-based haemostat in different fields of surgery—a systematic review. Expert Opinion on Biological Therapy, 2009. 9(7): p. 897-97.
30. Salzedas-Netto AA, A.H., Castro CC, Mattar RH, Medeiros KL, Linhares MM, Duarte AA, Chien ES, Marino GC, Matos CA, Lopes-Filho G, Martins JL, González AM, Impact of verseo on outcomes with TachoSil in Liver transplantation. Transplantation Proceedings 2010. 42: p. 507-10.
31. SeehoferDE, Weltzke-Schleker W, Neuhaus P. Biliary Complications After Liver Transplantation: Old Problems and New Challenges. American Journal of Transplantation, 2013. 13: p. 253-65.
32. Semer, NB, Awaiting Liver Transplantation. Transplantation 2015. 99(7): p. 48-49.
33. Surjan RC, Makdissi FF, Machado MA. Anatomical basis for the intrahepatic glissonian approach during hepatectomies. ABCD, arq. bras. cir. dig., June 2015, vol.28, no.2, p.128-131. ISSN 0102-6720
34. TachoSil®: fibrinogénio + trombina. Responsável técnico: Rafael de Santos. São Paulo: Takeda Pharma Ltda, B.d.r.
35. Tissieres, DDP. Pediatric liver transplantation: where do we stand? Where we are going to?. Expert Review of Gastroenterology & Hepatology, 2015.
36. Toti LAM, Manzia TM, Lenci I, Gunson B, Buckels JA, Mirza DF, et al. Reduction in bile leaks following adult split liver transplant using a fibrin-collagen sponge: A pilot study. Digestive and Liver Disease 2010. 42: p. 205-09.